Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the and ...

New findings from the CONFIDENCE trial show that combination therapy with finerenone and empagliflozin leads to significantly ...

There is a nationwide shortage of pediatric specialists, delaying care for many patients. In some cases, children wait weeks ...

Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® (pegcetacoplan) for C3 glomerulopathy (C3G ...

Rory Teeters, 7, has cystic fibrosis but with ongoing care in Rapid City from pediatric pulmonologist Dr. James Wallace, she's living her best life.

In the VALIANT study, EMPAVELI demonstrated a statistically significant 68% proteinuria reduction versus placebo at Week 26, which was sustained at one year. Additionally, patients treated with ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® ...

In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

BMJ Evidence-Based Medicine (BMJ EBM) publishes original evidence-based research, insights and opinions on what matters for health care. We focus on the tools, methods, and concepts that are basic and ...